IntroductionCervical cancer is the fourth most common cause of cancer-related death worldwide. High-risk locally advanced or recurrent/metastatic cervical cancers have a poor prognosis with routine treatments. The objective of this study is to analyze the data available in the literature on therapies and molecules currently in use to improve the prognosis of recurrent cervical cancer.Areas coveredAn extensive literature search was conducted by authors to identify relevant trials on various databases. Articles in English published until September 2023 that investigate different pharmacotherapy strategies for the treatment of recurrent cervical cancer, were included. Results of various pharmacological regimens including different combinations of chemotherapy, immune checkpoint inhibitors, DNA damage repair inhibitors and antibody-drug conjugates were analyzed.Expert opinionIn recent years, there have been significant improvements in the outcomes of recurrent/metastatic cervical cancer. However, these improvements do not address the unmet need in terms of oncological outcomes. The introduction of immunotherapy and targeted therapies showed advantages in cervical cancer patients. New therapies and combination strategies must be implemented. Centralization of care and enrollment in clinical trials are of paramount importance. Primary and secondary prevention remains the fundamental goal to reduce the burden of cervical cancer.

Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature / D'Oria, Ottavia; Bogani, Giorgio; Cuccu, Ilaria; D'Auge, Tullio Golia; Di Donato, Violante; Caserta, Donatella; Giannini, Andrea. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1744-7666. - 25:1(2024). [10.1080/14656566.2023.2298329]

Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature

D'Oria, Ottavia;Bogani, Giorgio;Cuccu, Ilaria;D'Auge, Tullio Golia;Di Donato, Violante;Caserta, Donatella;Giannini, Andrea
2024

Abstract

IntroductionCervical cancer is the fourth most common cause of cancer-related death worldwide. High-risk locally advanced or recurrent/metastatic cervical cancers have a poor prognosis with routine treatments. The objective of this study is to analyze the data available in the literature on therapies and molecules currently in use to improve the prognosis of recurrent cervical cancer.Areas coveredAn extensive literature search was conducted by authors to identify relevant trials on various databases. Articles in English published until September 2023 that investigate different pharmacotherapy strategies for the treatment of recurrent cervical cancer, were included. Results of various pharmacological regimens including different combinations of chemotherapy, immune checkpoint inhibitors, DNA damage repair inhibitors and antibody-drug conjugates were analyzed.Expert opinionIn recent years, there have been significant improvements in the outcomes of recurrent/metastatic cervical cancer. However, these improvements do not address the unmet need in terms of oncological outcomes. The introduction of immunotherapy and targeted therapies showed advantages in cervical cancer patients. New therapies and combination strategies must be implemented. Centralization of care and enrollment in clinical trials are of paramount importance. Primary and secondary prevention remains the fundamental goal to reduce the burden of cervical cancer.
2024
Cervical cancer; PD-L1; anti- angiogenic therapy; immune checkpoint inhibitor; novel therapeutics
01 Pubblicazione su rivista::01a Articolo in rivista
Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature / D'Oria, Ottavia; Bogani, Giorgio; Cuccu, Ilaria; D'Auge, Tullio Golia; Di Donato, Violante; Caserta, Donatella; Giannini, Andrea. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1744-7666. - 25:1(2024). [10.1080/14656566.2023.2298329]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1703680
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 0
social impact